← Back to Screener
Curanex Pharmaceuticals Inc Common Stock (CURX)
Price$0.30
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-45.71%
Price vs S&P 500 (4W)-6.18%
VGM Score37.65
Market Capitalization$8.59M
All Metrics
Book Value / Share (Quarterly)$0.28
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.40
Price vs S&P 500 (YTD)-16.62%
EPS (TTM)$-0.26
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-0.26
EPS (Annual)$-0.17
ROI (Annual)-37.66%
Gross Margin (Annual)17.04%
Cash / Share (Quarterly)$0.14
ROA (Last FY)-36.49%
EBITD / Share (TTM)$-0.26
Cash Flow / Share (Annual)$-0.37
P/B Ratio1.06x
P/B Ratio (Quarterly)1.80x
Net Income / Employee (Annual)$-704,200
Net Interest Coverage (TTM)-493.74x
ROA (TTM)-82.11%
EPS Incl Extra (Annual)$-0.17
Current Ratio (Annual)81.93x
Quick Ratio (Quarterly)31.22x
3-Month Avg Trading Volume3.01M
Revenue / Employee (TTM)$0
P/S Ratio (Annual)330.56x
Asset Turnover (Annual)2.54x
52-Week High$9.18
EPS Excl Extra (Annual)$-0.17
26-Week Price Return-37.78%
Quick Ratio (Annual)36.29x
13-Week Price Return-24.06%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)62.87x
Enterprise Value$4.58M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-77.81%
Cash / Share (Annual)$0.18
3-Month Return Std Dev84.51%
Net Income / Employee (TTM)$-1,206,300
ROE (Last FY)-37.66%
EPS Basic Excl Extra (Annual)$-0.17
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.26
ROI (TTM)-84.42%
Revenue / Share (Annual)$0.00
Year-to-Date Return-8.46%
5-Day Price Return-8.15%
EPS Normalized (Annual)$-0.17
Net Profit Margin (Annual)-77.81%
Month-to-Date Return-8.90%
EBITD / Share (Annual)$-0.17
Operating Margin (Annual)-77.81%
LT Debt / Equity (Quarterly)1.31x
EPS Basic Excl Extra (TTM)$-0.26
P/B Ratio (Annual)0.84x
Book Value / Share (Annual)$0.40
Price vs S&P 500 (13W)-32.31%
Beta0.41x
P/FCF (Annual)2573.22x
Revenue / Share (TTM)$0.00
ROE (TTM)-85.41%
52-Week Low$0.26
mGradeD
vgmGradeD
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CURXCuranex Pharmaceuticals Inc Common Stock | — | — | D | $0.30 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Curanex Pharmaceuticals develops botanical-based drugs targeting unmet medical needs in inflammatory diseases. Its lead compound, Phyto-N, is in preclinical development for six indications including ulcerative colitis, atopic dermatitis, type 2 diabetes, and NAFLD.